Emapalumab

11/28/2023 - "Exposure-safety relationship for patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab."
03/29/2023 - "Due to a paucity of available data on emapalumab, additional data are needed to establish its role in hemophagocytic lymphohistiocytosis treatment."
03/29/2023 - "Successful use of emapalumab in refractory hemophagocytic lymphohistiocytosis in a child with Chédiak-Higashi syndrome: a case report."
05/01/2021 - "Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis."
07/01/2020 - "Emapalumab for the treatment of hemophagocytic lymphohistiocytosis."

01/01/2022 - "To illustrate, we describe a patient with B-cell acute lymphoblastic leukemia who developed refractory grade 4 CRS following CD19-directed chimeric antigen receptor T-cell therapy, treated with tocilizumab, methylprednisolone, siltuximab, and the IFNγ inhibitor emapalumab, with complete remission from leukemia for 12 months. "

01/01/2022 - "To illustrate, we describe a patient with B-cell acute lymphoblastic leukemia who developed refractory grade 4 CRS following CD19-directed chimeric antigen receptor T-cell therapy, treated with tocilizumab, methylprednisolone, siltuximab, and the IFNγ inhibitor emapalumab, with complete remission from leukemia for 12 months. "

07/01/2020 - "She was markedly responsive to IFN-γ blockade with emapalumab that eliminated her fevers and all MAS-associated laboratory abnormalities. "

11/28/2023 - "Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. "
01/01/2023 - "Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients."
07/01/2020 - "HLH is a disorder characterized by hypercytokinemia in the setting of unbridled immune activation, and emapalumab represents the first therapeutic developed to address the underlying pathophysiology of HLH. "
05/01/2021 - "Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors."
01/01/2021 - "While the cytokine storm abated after administration of multiple immune modulatory therapies including dexamethasone, etoposide, intravenous immune globulin, anakinra, as well as the interferon gamma antagonist emapalumab, multiple organ dysfunction syndrome progressed. "